# SeqOnce Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seqonce-biosciences

- Industry: Biotechnology
- Headquarters: Pasadena, US
- Website: www.seqonce.com
- Total disclosed funding: $1.2M
- Latest round: Seed (May 8, 2018)
- Investors on record: 3

## About

SeqOnce Biosciences focuses on developing and producing advanced genomic assays and reagents to enhance research and diagnostic capabilities in molecular biology and conservation.Founded in 2014 and headquartered in Pasadena, US, SeqOnce Biosciences specializes in genomic research solutions. The company was co-founded by Chris Angermayer, who has a history of founding other biotech ventures. In May 2018, SeqOnce raised USD 1.2 mn in a SEED round led by Mount Wilson Ventures, with participation from Embark Ventures and Wavemaker Three-Sixty Health. The total amount raised by the company is USD 1.2 mn, with four notable deals completed to date.SeqOnce Biosciences specializes in developing advanced assays and reagents aimed at enhancing genomic research and diagnostic capabilities. Their offerings include high-quality qPCR assays and next-generation sequencing (NGS) products for rapid pathogen nucleic acid detection. Notable products include the H5N1 Avian Influenza Panel and various microbiota panels, intended for use by researchers, clinical laboratories, and conservationists. The company primarily markets its products in North America, Europe, and parts of Asia, targeting academic institutions, biotech firms, and governmental research organizations engaged in molecular biology and conservation efforts.SeqOnce generates revenue through direct sales of its assays and reagents to clients in the scientific and medical research sectors. Transactions are typically conducted on a B2B basis, with products sold either as one-time orders or through recurring procurement agreements for ongoing projects. The pricing structure reflects the specialized nature of their offerings, with flagship products such as the SeqOnce Amplification Master Mixes being pivotal to the company's revenue model. Revenue transactions are facilitated by Field Applications Specialists, ensuring comprehensive support for clients, thereby enhancing customer retention and satisfaction.SeqOnce Biosciences plans to leverage recent funding to expand its product offerings and enter new markets. The company is focused on designing additional pathogen detection panels and enhancing its qPCR assays, with new products expected to be launched by late 2019. Furthermore, SeqOnce aims to expand its presence in Asia and Europe by 2020. The USD 1.2 mn raised in May 2018 will be utilized for product development and market expansion initiatives.

## Funding rounds

- Seed, May 8, 2018, $1.2M — Embark Ventures, Mount Wilson Ventures, Wavemaker Three-Sixty Health

## Investors

- Embark Ventures (https://capitalatlas.ai/funds/embark-ventures) — Seed
- Mount Wilson Ventures (https://capitalatlas.ai/funds/mount-wilson-ventures) — Seed
- Wavemaker Three-Sixty Health (https://capitalatlas.ai/funds/wavemaker-three-sixty-health) — Seed